Moderna, Inc.
NASDAQ:MRNABiotechnology
+$2.48 today
- Market cap
- $79.63B
- Beta
- 1.03
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$8.09
Volume 6.91M
Average 6.53M
MRNA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Moderna, Inc.NASDAQ: MRNA
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation growth accelerates
Q3 FY2026 stock-based compensation of $127M rose 1.6% year over year, ahead of the -25.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at +28.8% a year.
Context
- Stock-based compensation amounted to 24.8% of revenue in FY2025, up 11.4 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1.6% holds above the trailing-twelve-month pace of -25.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 483M USD
- Year-over-year change
- +12.6%
- 4-year CAGR
- +35.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 483M | +12.6% |
| FY2024 | 2024-12-31 | 429M | +40.7% |
| FY2023 | 2023-12-31 | 305M | +35.0% |
| FY2022 | 2022-12-31 | 226M | +59.2% |
| FY2021 | 2021-12-31 | 142M | — |
Stock-Based Compensation vs competitors
How MRNA compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -25.9% is the 4th highest of 7, against a peer median of -6.9%.
- Stock-based compensation amounts to 13.9% of revenue for MRNA, versus a peer median of 1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $947M USD | +14.9% | -2.9% | 1.5% | |
| LTM Sep 2026 | $351M USD | -25.9% | +28.8% | 13.9% | |
| LTM Jun 2026 | $188.47M USD | +66.5% | +80.4% | — | |
| LTM Mar 2026 | $35.01M USD | +17.1% | -21.7% | 53.5% | |
| LTM Mar 2026 | $33.45M USD | -28.6% | -34.9% | 5.6% | |
| LTM Mar 2026 | $23.07M USD | -33.2% | -6.0% | 50.9% | |
| LTM Mar 2026 | $3.06M USD | -44.1% | -45.0% | — | |
| LTM Jun 2026 | £0 GBP | — | — | 0.0% | |
| LTM Jun 2026 | €0 EUR | — | — | 0.0% | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding MRNA) | — | -6.9% | -13.8% | 1.5% | |
Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 12.2B | 8.36B | (4.71B) | (3.56B) | (2.82B) |
| Depreciation & Amortization | 232M | 348M | 621M | 189M | 215M |
| Deferred Income Tax | (318M) | (559M) | 828M | 0 | 0 |
| Stock-Based Compensation | 142M | 226M | 305M | 429M | 483M |
| Change in Working Capital | 1.31B | (3.46B) | (139M) | (78M) | 254M |
| Accounts Receivables | (1.78B) | 1.79B | 493M | 534M | 156M |
| Inventory | (1.39B) | 492M | 747M | 83M | (34M) |
| Accounts Payables | 204M | 240M | 13M | (69M) | (92M) |
| Other Working Capital | 4.28B | (5.98B) | (1.39B) | (626M) | 224M |
| Other Non-Cash Items | 54M | 59M | (19M) | 17M | (3M) |
| Operating Cash Flow | 13.62B | 4.98B | (3.12B) | (3B) | (1.87B) |
| Capital Expenditures | (284M) | (400M) | (707M) | (1.05B) | (192M) |
| Acquisitions (Net) | 0 | 0 | (85M) | 0 | 0 |
| Purchases of Investments | (12.65B) | (11.44B) | (3.78B) | (6.53B) | (5.77B) |
| Sales of Investments | 4.44B | 6.7B | 8.78B | 9.53B | 7.92B |
| Other Investing Activities | (30M) | (40M) | 0 | 0 | (10M) |
| Investing Cash Flow | (8.52B) | (5.18B) | 4.21B | 1.95B | 1.95B |
| Debt Repayment | (140M) | (184M) | (270M) | (10M) | 539M |
| Common Stock Issued | 124M | 65M | 46M | 66M | 35M |
| Common Stock Repurchased | (857M) | (3.33B) | (1.15B) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 19M |
| Financing Cash Flow | (873M) | (3.45B) | (1.38B) | 56M | 593M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 2M |
| Net Change in Cash | 4.22B | (3.64B) | (289M) | (999M) | 668M |
| Free Cash Flow | 13.34B | 4.58B | (3.83B) | (4.06B) | (2.07B) |
Moderna, Inc.
NASDAQ:MRNA
Intrinsic Alpha fair value
Locked
Current Price
$196.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.